This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (13)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Diabetes Mellitus  • Alzheimer Disease  • Dementias  • Neuroendocrinology  • Neurology, Other  • Alert me on articles by topic

Results From the Framingham Study

Abimbola Akomolafe, MD, MPH, MS; Alexa Beiser, PhD; James B. Meigs, MD, MPH; Rhoda Au, PhD; Robert C. Green, MD, MPH; Lindsay A. Farrer, PhD; Philip A. Wolf, MD; Sudha Seshadri, MD

Arch Neurol. 2006;63:1551-1555.

Background  Diabetes mellitus (DM) could increase the risk of Alzheimer disease (AD) through several biologically plausible pathways, but the relationship between DM and the development of AD remains uncertain.

Objective  To compare the risk of developing AD in subjects with and without DM.

Design  Prospective community-based cohort study.

Participants  Framingham Study Original cohort participants who were dementia free and attended the 16th biennial examination (n = 2210 persons, 1325 women; mean age, 70 years).

Main Outcome Measures  Relative risk of incident AD (criteria from the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association) associated with baseline DM (casual plasma glucose 200 mg/dL [11.1 mmol/L] or use of insulin or a hypoglycemic drug) in overall group and within subgroups defined by apolipoprotein E genotype and plasma homocysteine levels; models were adjusted for age, sex, and cardiovascular risk factors.

Results  At baseline, 202 participants (9.1%) had DM. During the follow-up period (mean, 12.7 years; range, 1-20 years), 17 of 202 persons with DM (8.4%) and 220 of 2008 persons without DM (11.0%) developed AD, yielding a relative risk of 1.15 (95% confidence interval, 0.65-2.05). Among subjects without an apolipoprotein E 4 allele or elevated plasma homocysteine levels, 44 of 684 persons (6.4%) developed AD; relative risk for AD comparing diabetic patients with nondiabetic patients was 2.98 (95% confidence interval, 1.06-8.39; P = .03). The effect was strongest in persons aged 75 years or older with a relative risk of 4.77 (95% confidence interval, 1.28-17.72; P = .02).

Conclusion  Diabetes mellitus did not increase the risk of incident AD in the Framingham cohort overall; however, DM may be a risk factor for AD in the absence of other known major AD risk factors.

Author Affiliations: Department of Medicine, Morehouse School of Medicine, Atlanta, Ga (Dr Akomolafe); the Departments of Biostatistics (Dr Beiser), Medicine [Genetics Program] (Dr Farrer), and Neurology (Drs Au, Green, Wolf, and Seshadri), Schools of Public Health and Medicine, Boston University, Boston, Mass; the General Medicine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dr Meigs); and the National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Mass.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Enhanced Risk for Alzheimer Disease in Persons With Type 2 Diabetes and APOE {varepsilon}4: The Cardiovascular Health Study Cognition Study
Irie et al.
Arch Neurol 2008;65:89-93.
ABSTRACT | FULL TEXT  

Vascular factors predict rate of progression in Alzheimer disease
Mielke et al.
Neurology 2007;69:1850-1858.
ABSTRACT | FULL TEXT